Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
24
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
9
users have commented on this narrative
25
users have followed this narrative
11 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
22
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Commercial International Bank Egypt (CIB)E
AN
AnalystHighTarget
Consensus Narrative from 10 Analysts
Egypt's Expanding Middle Class And Digitization Will Accelerate Banking Demand
Key Takeaways Digital expansion and innovative products position CIB for sustainable growth, outperforming market expectations in retail loans, fee income, and deposit acquisition. Operational transformation and capital strength underpin long-term profitability, enabling superior cost efficiency, special dividends, and strategic market moves.
View narrative
ج.م160.68
FV
38.4% undervalued
intrinsic discount
11.47%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Aeon
AN
AnalystLowTarget
Consensus Narrative from 7 Analysts
Overvaluation Will Exacerbate Legacy Retail Struggles Despite Digital Upside
Key Takeaways Reliance on legacy retail and slow adaptation to digital trends leave Aeon vulnerable to margin pressure, falling foot traffic, and relentless online competition. Demographic headwinds, emerging market risks, and costly regulatory adaptation threaten long-term profitability and stable bottom-line growth.
View narrative
JP¥1.65k
FV
238.0% overvalued
intrinsic discount
1.46%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Glenmark Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Global Aging And Emerging Markets Will Fuel Specialty And Biosimilars
Key Takeaways Expansion in high-demand Indian and US markets, alongside specialty product rollouts, is expected to accelerate earnings and broaden global revenue streams. Strategic investments in manufacturing efficiency and global diversification should enhance margins, cash flow, and resilience against market and regulatory risks.
View narrative
₹2.93k
FV
34.0% undervalued
intrinsic discount
13.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Astellas Pharma
AN
AnalystLowTarget
Consensus Narrative from 14 Analysts
Patent Expirations And Price Reforms Will Erode Future Margins
Key Takeaways Loss of exclusivity for major drugs and persistent R&D challenges threaten future revenue stability and hinder the replacement of expiring blockbusters. Pricing pressures, regulatory risks, and supply chain complexities increase margin volatility and operational uncertainty across key global markets.
View narrative
JP¥1.30k
FV
30.2% overvalued
intrinsic discount
-6.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Capitec Bank Holdings
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Digital Disruption And Regulatory Pressures Will Undermine Future Prospects
Key Takeaways Digital disruption and intense competition from fintechs and established players threaten Capitec's traditional revenue streams and force costly technology investments. Economic headwinds and regulatory pressures heighten credit risk, compress margins, and limit innovation, undermining profitability and earnings quality.
View narrative
R2.91k
FV
26.3% overvalued
intrinsic discount
25.03%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
Straumann Holding
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Rising Regulation And Cost Pressures Will Curb Premium Dental Demand
Key Takeaways Erosion of demand for premium dental products threatens revenue growth, aggravated by cost pressures, tougher regulations, and intensifying global competition. Disruptive business models and commoditization risk undermining Straumann's traditional market dominance, shrinking the addressable market and compressing operating margins.
View narrative
CHF 85.00
FV
13.0% overvalued
intrinsic discount
6.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Sonova Holding
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
Low-Cost Rivals And Digital Shifts Will Erode Premium Pricing
Key Takeaways The rise of low-cost competitors, new technologies, and commoditization threatens Sonova's pricing power, market share, and overall growth prospects. Regulatory pressures, rising costs, and declining clinic profitability are undermining margins and limiting the company's ability to sustain earnings.
View narrative
CHF 189.00
FV
23.4% overvalued
intrinsic discount
4.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Associated British Foods
AN
AnalystLowTarget
Consensus Narrative from 17 Analysts
US Tariffs And Cost Pressures Will Squeeze Margins
Key Takeaways Heightened regulatory and input cost pressures, along with slow digital adoption, threaten group margins and risk undermining future revenue growth and profitability. Shifting consumer preferences and underperformance in key segments could erode market share, dilute returns on capital, and stagnate or reduce group earnings.
View narrative
UK£17.50
FV
32.2% overvalued
intrinsic discount
2.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
2 days ago
author updated this narrative
NEC
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Rising Labor Costs And GDPR Mandates Will Crimp Operating Margins
Key Takeaways Rising compliance and labor costs, along with legacy dependencies, threaten NEC's profitability and limit growth in digital and international markets. Increased competition from hyperscalers and rapid IT commoditization risk eroding NEC's market relevance and pricing power.
View narrative
JP¥3.50k
FV
32.5% overvalued
intrinsic discount
1.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Value any company in seconds
Popular companies